Author Archives: admin


The Beljanski Foundation Launches Annual Integrative Cancer Conference October 13-15 in Jacksonville, Florida – EIN News

The conference offers a chance to bring together people from all backgrounds to discuss cancer-related topics and research.

Sylvie Beljanski

The event will support breast cancer stem cell research funded by the Beljanski Foundation, a 501(c)(3) non-profit conducting scientific research into natural plant extracts for cancer treatment and cancer prevention. According to Nathan Crane, Conference and Strategic Solutions Director of the Beljanski Foundation, "the conference will offer cutting-edge solutions, science, and support for putting an end to cancer with top doctors and cancer conquerors from holistic, functional, and integrative medicine." Breast cancer stem cell research is crucially important because breast cancer stem cells are thought to be responsible for the recurrence and metastasis of breast cancer. Unlike other cancer cells, which can be killed by chemotherapy and radiation therapy, breast cancer stem cells have the ability to survive and become resistant to these treatments, leading to tumor regrowth and metastasis. Early research has shown very promising results with non-toxic natural compounds. However, more funding is needed to confirm the benefits on breast cancer stem cells, and this event aims to spread this awareness.

Since August, the Beljanski Foundation, Panacea Community, LLC, and Healing Life International, LLC have partnered to bring this three-day event to fruition. The conference will feature presentations by the top holistic doctors and leaders in functional medicine and provide "education, inspiration, community, networking, presentations, workshops, technology, scientific breakthroughs, entertainment, and fundraising." There will also be a Friday Night Black-Tie Gala dinner.

The Beljanski Foundation is committed to treating cancer holistically and to "study and share knowledge of effective non-toxic, natural answers that work both alone and in synergy with traditional western medicine to cure cancer and other chronic diseases the natural way." Sylvie Beljanski began the Beljanski Foundation to continue her father's work. Known as "the father of environmental medicine," Mirko Beljanski, Ph.D. worked to bring "nature and science together to improve the health and well-being of people," states Sylvie Beljanski. Through the Beljanski Foundation, Dr. Mirko Beljanski's research only continues.

"For a different outcome, let's look at cancer differently. After all, doing the same thing again and again and hoping for a different result is the definition of insanity," continues Beljanski.

Super early bird tickets are available until April 30, 2023. To register and learn more about "Winning the War on Cancer" - The Beljanski Integrative Cancer Conference, follow this link: https://integrativecancerconference.com

To learn more about the Beljanski Foundation and its impact on natural solutions to cancer, click here: https://beljanski.org.

Homepage

Aurora DeRoseBoundless Media Inc.+1 951-870-0099email us here

View original post here:
The Beljanski Foundation Launches Annual Integrative Cancer Conference October 13-15 in Jacksonville, Florida - EIN News

Closing the IP and innovation gender gap in Canada – WIPO

April 2023

By David Durand, founder of DURAND Lawyers and co-founder of MVIP, as well as sitting President of FORPIQ (agenda), Montral, Canada

In the world of innovation, creation and entrepreneurship, gender gaps or disparities should not exist. Science, whether undertaken by a man or a woman, is science, and should be judged solely on the merits of its findings. Yet, research reveals a number of barriers that prevent women from contributing to scientific endeavor and its resulting innovations.

According to a report by the Canadian Intellectual Property Office, Processing Artificial Intelligence: Analysis from a Canadian Perspective, At the international scale, there was one female identified for every three males involved in AI patenting. By comparison, for patented inventions containing at least one Canadian researcher, that ratio decreases to one female for every six male researchers.

Similarly, data from WIPO reveal that only 16.5 percent of inventors named in international patent applications in 2020 were women. While this share has increased by 3.8 percentage points, progress is slow. WIPO estimates that, at the current pace, gender parity among PCT-listed inventors will only be reached in 2058.

These ratios are concerning, as there is no doubt that women have and continue to be active contributors to the sciences, despite being identified in certain cases as unsung heroes". That is why it is important to encourage more women to engage with the intellectual property (IP) system so they can leverage the value of their work. When more women engage in IP, we all win because diversity in innovation means more talent, more new perspectives, and increased chances of finding solutions to the complex challenges we face.

The Forum International de la Proprit Intellectuelle - Qubec (FORPIQ) promotes the uptake of intellectual property across Canada via its conference and support from its partner network, organizing committee and membership. In honor of Word Intellectual Property Day 2023 and this years campaign theme, Women and IP: Accelerating Innovation and Creativity, FORPIQ wishes to highlight some of Canadas trailblazing women inventors, creators and entrepreneurs. These individuals exemplify the can do attitude of women and their ground-breaking work.

Improving heel-to-toe gait for improved mobility: Dr. Nancy Mayo, from the Division of Clinical Epidemiology, McGill University, became an entrepreneur in her late sixties. She founded Physio Biometrics Inc., in August 2019. Although no one was interested in her initial 2014 proposal, Dr. Mayo persisted in her biofeedback research to improve heel-to-toe gait for greater stability and improved mobility.

She has created a wearable sensor, Heel2ToeTM, which clips to the outside of a walking shoe. The device provides positive auditory feedback in real time when the wearer makes a good step - one that starts with a strong heel strike.

Today, Physio Biometrics has 135 prototypes of its sensor, all of which are on sale or being used in research projects with seniors and people with Parkinsons disease.

To ensure development of the sensor and its associated algorithms, Dr. Mayo collaborated with a colleague to secure grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC). This early funding opened up other opportunities to secure research funds from Healthy Brains for Healthy Lives (HBHL) and McGill Innovation Fund among others, to support innovation and provide employment for highly skilled people within her company. Additional revenue generated from workshops and the sale of the devices are being reinvested in the company to ensure the technology continues to evolve in response to consumers needs.

Dr. Mayo notes that becoming an entrepreneur can be difficult because once you start, you cant take your foot off the gas. The role of entrepreneur gets added on to other roles that women scientists take on: researcher, educator, inventor, family caregiver. The competitive nature of being an entrepreneur can mean letting go of other important roles. When confronted with barriers, Dr. Mayo says you can either step up or give up. Giving up is not in Dr. Mayos DNA, as seen from her achievements, including the publication of over 300 scientific papers. Dr. Mayo continues to excel in her field.

Becoming an entrepreneur can be difficult because once you start, you cant take your foot off the gas.

Dr. Mayos words of wisdom to future entrepreneurs, are learn your markets and consumers and provide them with the product that meets their needs, especially when they need a device that allows them to walk better.

Diagnosing infertility in men: Dr. Sarah Kimmins works for the research center of the Centre Hospitalier de lUniversit de Montral (CHUM), Department for Pathology and Cell Biology at the University of Montreal and the Department of Pharmacology and Therapeutics at McGill University. She is an epigeneticist, which means she studies how human behavior and the environment have an impact on the way our genes work.

Dr. Kimmins has developed a fertility diagnostic for men called HisTurn, based on biomarkers of the sperm epigenome (biochemical markers associated with DNA).

After reviewing and assessing Dr. Kimmins Report of Invention to the McGill Office of Innovation + Partnerships, the University took on the process of protecting the invention. McGill University also collaborated with Axelys to further support the development of the technology, with Axelys providing insights to support the technology transfer, implementation and commercialization of the HisTurn diagnostic.

According to Dr. Kimmins, the clinical adoption of HisTurn will fill a technology and health-need gap by accurately diagnosing infertility in men and providing clinicians with actionable information to choose the most appropriate treatment plan.

Dr. Kimmins explains that she and the McGill Office of Innovation + Partnerships worked with a patent agent to determine the best IP strategy to adopt to commercialize the diagnostic.

The support of our patent agent was invaluable, as it meant our team had access to the relevant expertise and understanding in the field of science in which I work, as well as deep knowledge of the law and patenting process, which can be tricky to navigate when including epigenomic targets, Dr. Kimmins explains.

With respect to the gender gap in science, technology, engineering and mathematics (STEM), Dr. Kimmins says, studies have shown that world-wide women are less likely to be awarded the same grant dollars as men, are allocated smaller lab space and start-up packages, and have increased demands placed on them for mentoring, teaching and service. They are also less likely to have their publications accepted in journals with a high-impact factor. Consequently, women allocate less time and resources to commercializing their science. Until equity is achieved in science, women will continue to be under-represented in patenting, she says.

Dr. Kimmins believes that more scholarships and financial programs should be awarded to underrepresented students (i.e., first generation migrants, low-income students, and others) to enable more talented people to take advantage of opportunities in STEM.

Until equity is achieved in science, women will continue to be under-represented in patenting.

Dr. Kimmins also believes that many of the skills learned as a principal investigator in the laboratory are transferable to entrepreneurial ventures. Running a lab includes securing millions of dollars for its operation and managing and inspiring a team of researchers towards a common goal. You are also constantly presenting your science to different communities, including the public, clinicians and other scientists. So having effective communication skills is essential, Dr. Kimmins explains.

Programs that promote women and their successes are key to attracting more young women to the field of innovation, Dr. Kimmins says.

Doctors Mayo and Kimmins agree that access to flexible funding to cover costs of patenting and to leverage matching funds to secure larger financial streams, is a key to translating an idea into a successful business. The two entrepreneurs applaud, McGills innovation fund (MIF), founded in Autumn 2021 to support entrepreneurial innovation by awarding grants to researchers seeking to commercialize new technologies and discoveries.

The fund seeks to help researchers bridge the valley of death, that precarious interval during which an invention emerges from the lab and makes its way to the market. Thats when the need for financial support is most acute, explains Dr. Mark Weber, Director of Innovation and Partnerships at the McGill Office of Research and Innovation.

To further support women in business, in September 2022, the Business Development Bank of Canada (BDC) launched a CAD 500 million Thrive Platform to assist trailblazing women-led companies to succeed and become tomorrows global leaders. The platform seeks to ensure that women entrepreneurs have access to everything they need to thrive and have a lasting impact on the economy. Its unique offering includes early stage venture capital investment for women-led businesses, strategic investment in women-led and focused funds, as well as emerging models working alongside ecosystem partners to provide equity investments to women-led businesses at the earliest stages of development.

The Innovation Asset Collective also offers grants for women in IP, provided that eligibility requirements are satisfied. The Government of Qubec has also invested CAD 8 million to increase the number of women in STEM, among other initiatives.

Promoting greater IP awareness among women scientists is an important step towards narrowing the IP and innovation gap.

Promoting greater IP awareness among women scientists is an important step towards narrowing the IP and innovation gap. But these efforts need to be complemented by a commitment to provide mentorship and leadership to younger generations in STEM. And that means changing perceptions and mindsets about innovation and IP well before young women begin their studies or pursue their academic careers.

Acknowledgement(s): The author would like to thank Drs. Kimmins, Mayo and Weber, as well as the BDC for their contributions to this article.

Me David Durand, B.Sc. (chem.), LL.L, lawyer and trademark agent, is the founder of DURAND Lawyers and co-founder of MVIP, the sitting president of FORPIQ, and is an advisor to the National Crowdfunding and Fintech Association of Canada (NCFA). Mr.Durand has appeared before the Canadian House of Commons Standing Committee on Finance regarding crypto-assets within its statutory review of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act and was invited to submit its co-authored brief titled Dont block the blockchain: How Canada can guard against money laundering while maintaining global competitiveness. He has also participated in other consultations regarding the regulation of crypto-asset trading platforms (CSA/IIROC, IOSCO - CR02/2019 ), global stablecoin arrangements before the international Financial Stability Board (FSB), the modernization of Ontarios capital markets (jointly with NCFA) and the transfer of personal data across borders (joint submission with the Chamber of Digital commerce) before the Office of the Privacy Commissioner of Canada. He has also recently appeared before the Canadian House of Commons Standing Committee on Science and Research to talk about support for the commercialization of intellectual property (evidence).

Mr. Durand was recently accepted as a subject matter expert for the Standards Council of Canadas Canadian Mirror committee ISO/TC279 on innovation management standards, as well as the IEC SEG15 committee on the metaverse. He has also taught courses on IP law at the University of Ottawa, and was recently published in Durand, D., Mulcair, C. (2023). Whats the Big Idea? The Crossroads Between Investment and IP. In: Bader, M.A., Szerolu-Melchiors, S. (eds) Intellectual Property Management for Start-ups. Management for Professionals. Springer, Cham. https://doi.org/10.1007/978-3-031-16993-9_8.

See the original post here:
Closing the IP and innovation gender gap in Canada - WIPO

Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

View original post here:
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative…

SHANGHAI, China, April 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that positive interim event-free survival (EFS) results from the Neotorch study were presented at the ASCO April Plenary Series.

More here:
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two (32) new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

Read more:
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

See the article here:
Seer to Report First Quarter 2023 Financial Results on May 9, 2023

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of…

CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.

Read more from the original source:
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of...

Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023

FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Here is the original post:
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023